LAKE ZURICH, Ill., May 23, 2017 – Fresenius Kabi announced today it has introduced Vecuronium Bromide for Injection in the United States. The lyophilized product is available in two strengths: 10mg per vial1 and 20mg per vial2.
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
“The introduction of another neuromuscular blocker from Fresenius Kabi demonstrates our further commitment to supporting anesthesiologists and other health care professionals with a broad line of medicines used in operating rooms and throughout hospitals,” said John Ducker, president and chief executive officer of Fresenius Kabi USA.
About Vecuronium Bromide for Injection
Vecuronium Bromide for Injection is a non-depolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.
Important Safety Information
Vecuronium Bromide for Injection should be administered by adequately trained individuals familiar with its actions, characteristics, and hazards.
Vecuronium bromide is contraindicated in patients known to have a hypersensitivity to it. Severe anaphylactic reactions to neuromuscular blocking agents, including Vecuronium Bromide, have been reported. These reactions have in some cases been life-threatening and fatal. The administration of Vecuronium Bromide has been associated with rare instances of hypersensitivity reactions (bronchospasm, hypotension and/or tachycardia, sometimes associated with acute urticaria or erythema).
Experience in patients with cirrhosis or cholestasis has revealed prolonged recovery time. Conditions associated with slower circulation time in cardiovascular disease, old age, edematous states may contribute to a delay in onset time.
In the Intensive Care Unit, appropriate monitoring is recommended to help preclude possible prolongation of a neuromuscular blockade. The risks and benefits of therapy must be considered when there is a need for long-term mechanical ventilation.
Patients known to have myasthenia gravis or the myasthenic (Eaton-Lambert) syndrome may have profound effects to small doses of Vecuronium.
The Important Safety Information does not include all the information needed to use Vecuronium Bromide for Injection safely and effectively. Please click US-PH-Vecuronium_Bromide_FK-451512A_Nov_2016_v2-PI.pdf for the full prescribing information for Vecuronium Bromide for Injection, including boxed warning.
To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.
11 mg/mL when reconstituted to 10 mL
21 mg/mL when reconstituted to 20 mL